Tucidinostat
- Generic Name
- Tucidinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Tofacitinib Combined With Chidamide in R/R ENKTCL
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 20
- Registration Number
- NCT03598959
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Phase II Umbrella Study Directed by Next Generation Sequencing
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
- Conditions
- Interventions
- Drug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-mercaptopurine.Drug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: KaryotypingDrug: ChidamideDiagnostic Test: PET-CT scan
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03564704
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT03564470
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Interventions
- Drug: ChidamideDrug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-MercaptopurineDrug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 66
- Registration Number
- NCT03494634
- Locations
- 🇨🇳
Cancer Center of Sun Yat-Sen University (CCSU), Guangzhou, Guangdong, China
Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03410004
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 50
- Registration Number
- NCT03336632
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 102
- Registration Number
- NCT03321890
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Qingdao University
- Target Recruit Count
- 30
- Registration Number
- NCT03273452
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.